Menopause Lab Panel: Which Hormones to Track

← Back to Journal

Menopause is not a single event - it is a transition that unfolds over years. And while hot flashes and missed periods get most of the attention, the hormonal shifts of menopause can affect virtually every system in your body: your brain, bones, heart, metabolism, sleep, and mood.

The right lab tests at the right time can help you understand where you are in this transition, identify emerging health risks, and make informed decisions about treatment - including whether hormone replacement therapy (HRT) may be right for you.

Understanding the Menopausal Transition

Perimenopause

The transition can begin in your early to mid-40s (sometimes late 30s) and lasts an average of 4-8 years. During perimenopause:

Estrogen can fluctuate wildly - it can spike higher than in your 20s before eventually declining
Progesterone can drop first as cycles can become anovulatory more frequently
FSH can begin to rise as the pituitary gland works harder to stimulate the ovaries
Symptoms can emerge: irregular periods, sleep disruption, mood changes, hot flashes

Menopause

Officially defined as 12 consecutive months without a period, the average age of menopause is 51. After this point:

Estradiol can drop by approximately 85%
FSH can rise and stay elevated (can be above 30 mIU/mL)
Testosterone can decline gradually (about 50% reduction by menopause)
Health risks can shift as protective hormonal effects diminish

The Essential Menopause Lab Panel

1. FSH (Follicle-Stimulating Hormone)

FSH is the classic marker used to assess menopausal status. As the ovaries produce less estrogen, the pituitary gland can release more FSH in an attempt to stimulate egg production.

Premenopausal range: 3-10 mIU/mL (follicular phase)
Perimenopausal: Can fluctuate, may be 10-25 mIU/mL
Postmenopausal: Can be above 30 mIU/mL, and may be 40-100+ mIU/mL

Important caveat: During perimenopause, FSH can fluctuate dramatically from month to month. A single normal FSH can't rule out perimenopause. Serial testing over time can provide a more accurate picture.

2. Estradiol (E2)

Estradiol is the primary and most potent form of estrogen. Tracking its decline can help gauge where you are in the transition and whether you may benefit from estrogen therapy.

Premenopausal: 30-400 pg/mL (varies with cycle phase)
Perimenopausal: Erratic, can be very high or very low
Postmenopausal: Can be below 30 pg/mL, and may be below 20 pg/mL

3. Progesterone

Progesterone can be the first hormone to decline in the menopausal transition, as anovulatory cycles may produce little to no progesterone. Low progesterone in the presence of fluctuating estrogen can contribute to:

Heavy, irregular periods
Insomnia (progesterone can promote sleep)
Anxiety and mood instability
Estrogen dominance symptoms

4. Testosterone and SHBG

Testosterone often receives less attention during menopause, but its decline may contribute significantly to:

Low libido - one of the most common and distressing symptoms
Fatigue and loss of motivation
Reduced muscle mass and difficulty maintaining fitness
Brain fog and decreased cognitive sharpness

SHBG can increase with oral HRT, which can further reduce available free testosterone.

5. Thyroid Panel

Thyroid disease can become increasingly common as women age, and thyroid dysfunction symptoms can closely mimic menopause symptoms - fatigue, weight gain, mood changes, brain fog, hair loss, and sleep disturbance. It is essential to rule out thyroid issues rather than attributing everything to menopause.

A complete thyroid panel should include:

TSH - primary screening marker
Free T4 - the main hormone the thyroid releases
Free T3 - the most metabolically active thyroid hormone
TPO antibodies - screens for Hashimoto thyroiditis (autoimmune thyroid disease, which can peak in prevalence around menopause)

6. Bone Health Markers

Estrogen plays a critical protective role in bone health. After menopause, bone loss can accelerate significantly - women can lose up to 20% of their bone density in the first 5-7 years post-menopause.

Key markers include:

Vitamin D (25-hydroxyvitamin D) - essential for calcium absorption; optimal levels may be 40-60 ng/mL
Calcium - baseline assessment
Alkaline phosphatase - may point to bone turnover
Consider a DEXA scan (not a lab test but critical for bone density assessment)

7. Cardiovascular Risk Markers

Before menopause, estrogen can provide significant cardiovascular protection. After menopause, women's cardiovascular risk can increase to match that of men. Comprehensive lipid and metabolic testing becomes crucial:

Complete lipid panel - total cholesterol, LDL, HDL, triglycerides
Fasting insulin - insulin resistance can increase dramatically after menopause
Fasting glucose and HbA1c - screen for prediabetes and diabetes
hsCRP (high-sensitivity C-reactive protein) - inflammatory marker that may be linked to cardiovascular risk
Apolipoprotein B (ApoB) - may be a superior predictor of cardiovascular risk compared to LDL alone

8. Additional Markers

DHEA-S - adrenal hormone that can decline with age; may contribute to energy, libido, and well-being
Cortisol - chronic stress can compound menopausal symptoms
Vitamin B12 and folate - absorption can decline with age
Iron studies (ferritin, TIBC) - relevant especially during perimenopause when heavy periods can cause depletion, and post-menopause when levels may rise

When to Test and How Often

During Perimenopause

Baseline panel when symptoms first appear
Repeat every 6-12 months to track progression
Test on cycle day 2-5 if still menstruating (for FSH, estradiol, and other baseline hormones)
For progesterone, test mid-luteal phase (7 days post-ovulation) if periods are still occurring

Post-Menopause

Comprehensive panel within the first year of confirmed menopause
Annual monitoring of metabolic, thyroid, and bone health markers
Before and during HRT to guide dosing and monitor safety

Together, reproductive hormones, metabolic markers and thyroid markers give a comprehensive snapshot of the menopausal transition, so no thyroid-related contributor is overlooked. See what we test.

When HRT May Help

Hormone replacement therapy has undergone a significant reassessment in recent years. Current evidence supports its use in appropriate candidates:

Who May Benefit

Women with moderate to severe vasomotor symptoms (hot flashes, night sweats)
Women experiencing significant quality-of-life impairment from menopausal symptoms
Women at elevated risk of osteoporosis
Women in early menopause (before age 45) or with premature ovarian insufficiency
Women within 10 years of menopause onset or under age 60 (the "window of opportunity")

What the Evidence May Show

HRT initiated in the early menopausal window may provide cardiovascular protection
Transdermal estrogen (patches, gels) may carry lower risk of blood clots compared to oral forms
Micronized progesterone may be preferred over synthetic progestins for most women
Testosterone therapy for low libido is increasingly supported by evidence, though formulations specifically for women are limited

Lab Monitoring During HRT

Once on HRT, periodic monitoring can help ensure optimal dosing:

Estradiol levels (target depends on route and goals)
FSH (can decrease with adequate estrogen replacement)
Complete metabolic and lipid panels
Liver function tests (especially with oral formulations)

Tracking Your Transition

Menopause is not one-size-fits-all. Some women sail through with minimal symptoms; others find it profoundly disruptive. In either case, objective lab data empowers you to:

Understand your symptoms in the context of measurable hormonal changes
Identify emerging health risks (cardiovascular, metabolic, bone) early
Make informed treatment decisions based on your unique hormonal profile
Monitor the effectiveness of any interventions

Rather than guessing where you are in the menopausal transition, let the data guide you.

References

Harlow, S. D., et al. (2012). Executive summary of the Stages of Reproductive Aging Workshop +10. Journal of Clinical Endocrinology & Metabolism, 97(4), 1159-1168. PMID 22344196
The NAMS 2022 Hormone Therapy Position Statement Advisory Panel. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 767-794. PMID 35797481
Randolph, J. F., et al. (2011). Change in follicle-stimulating hormone and estradiol across the menopausal transition. Journal of Clinical Endocrinology & Metabolism, 96(3), 746-754. PMID 21159842
Eastell, R., et al. (2016). Postmenopausal osteoporosis. Nature Reviews Disease Primers, 2, 16069. PMID 27681935
El Khoudary, S. R., et al. (2020). Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association. Circulation, 142(25), e506-e532. PMID 33251828
Davis, S. R., et al. (2019). Global consensus position statement on the use of testosterone therapy for women. Journal of Clinical Endocrinology & Metabolism, 104(10), 4660-4666. PMID 31498871